JP2023552149A5 - - Google Patents
Info
- Publication number
- JP2023552149A5 JP2023552149A5 JP2023532443A JP2023532443A JP2023552149A5 JP 2023552149 A5 JP2023552149 A5 JP 2023552149A5 JP 2023532443 A JP2023532443 A JP 2023532443A JP 2023532443 A JP2023532443 A JP 2023532443A JP 2023552149 A5 JP2023552149 A5 JP 2023552149A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- paliperidone
- composition according
- palmitate
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025172891A JP2026027249A (ja) | 2020-11-30 | 2025-10-14 | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063119382P | 2020-11-30 | 2020-11-30 | |
| US63/119,382 | 2020-11-30 | ||
| PCT/EP2021/062144 WO2022111858A1 (en) | 2020-11-30 | 2021-05-07 | Dosing regimens associated with extended release paliperidone injectable formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025172891A Division JP2026027249A (ja) | 2020-11-30 | 2025-10-14 | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023552149A JP2023552149A (ja) | 2023-12-14 |
| JP2023552149A5 true JP2023552149A5 (https=) | 2024-05-17 |
| JP7792409B2 JP7792409B2 (ja) | 2025-12-25 |
Family
ID=75888042
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023532443A Active JP7792409B2 (ja) | 2020-11-30 | 2021-05-07 | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
| JP2025172891A Pending JP2026027249A (ja) | 2020-11-30 | 2025-10-14 | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025172891A Pending JP2026027249A (ja) | 2020-11-30 | 2025-10-14 | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11324751B1 (https=) |
| EP (2) | EP4025187B1 (https=) |
| JP (2) | JP7792409B2 (https=) |
| KR (1) | KR20230116837A (https=) |
| CN (1) | CN116507320A (https=) |
| AU (3) | AU2021387679B2 (https=) |
| CA (1) | CA3203448A1 (https=) |
| DK (1) | DK4025187T3 (https=) |
| ES (1) | ES2974822T3 (https=) |
| FI (1) | FI4025187T3 (https=) |
| HR (1) | HRP20240086T1 (https=) |
| HU (1) | HUE065387T2 (https=) |
| IL (1) | IL303251A (https=) |
| LT (1) | LT4025187T (https=) |
| MA (1) | MA71365A (https=) |
| MX (2) | MX2023006370A (https=) |
| PL (1) | PL4025187T3 (https=) |
| PT (1) | PT4025187T (https=) |
| RS (1) | RS65133B1 (https=) |
| SI (1) | SI4025187T1 (https=) |
| SM (1) | SMT202400075T1 (https=) |
| TW (2) | TWI897289B (https=) |
| WO (1) | WO2022111858A1 (https=) |
| ZA (1) | ZA202400851B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7839162B2 (ja) | 2020-11-30 | 2026-04-01 | ヤンセン ファーマシューティカ エヌ．ベー． | パルミチン酸パリペリドン製剤の再懸濁を確実にする方法 |
| ES2981035T3 (es) | 2020-11-30 | 2024-10-07 | Janssen Pharmaceutica Nv | Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada |
| MX2023006370A (es) | 2020-11-30 | 2023-08-07 | Janssen Pharmaceutica Nv | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. |
| MX2024002215A (es) | 2021-08-20 | 2024-05-10 | Janssen Pharmaceutica Nv | Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada. |
| WO2023030870A1 (en) * | 2021-08-30 | 2023-03-09 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254556A (en) | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
| US5158952A (en) | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| WO2006114384A1 (en) | 2005-04-25 | 2006-11-02 | Janssen Pharmaceutica N.V. | Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester |
| KR102318070B1 (ko) | 2007-12-19 | 2021-10-27 | 얀센 파마슈티카 엔.브이. | 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법 |
| WO2011042453A1 (en) | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| BR112012010195A2 (pt) | 2009-10-30 | 2016-04-26 | Janssen Pharmaceutica Nv | regime de dosagem associado a ésteres de paliperidona injetável de longa ação |
| ES2456917T3 (es) | 2011-05-31 | 2014-04-24 | Laboratorios Farmacéuticos Rovi, S.A. | Formulación de implante de paliperidona |
| WO2016157061A1 (en) | 2015-03-31 | 2016-10-06 | Wockhardt Limited | Aseptic wet milling process for paliperidone palmitate |
| RS65024B1 (sr) | 2015-04-07 | 2024-01-31 | Janssen Pharmaceutica Nv | Dozni režim za propuštene doze injektibilnih estara paliperidona sa produženim delovanjem |
| HK1254640A1 (zh) | 2015-06-19 | 2019-07-26 | Janssen Pharmaceutica, N.V. | 用於药物施用和混合的设备和方法及用於所述设备和方法的适当技术的训练 |
| PL3723760T3 (pl) * | 2017-12-14 | 2025-10-20 | SpecGx LLC | Jednoetapowy sposób mielenia w celu wytworzenia zmikronizowanych estrów paliperydonu |
| MX2023006370A (es) | 2020-11-30 | 2023-08-07 | Janssen Pharmaceutica Nv | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. |
| ES2981035T3 (es) | 2020-11-30 | 2024-10-07 | Janssen Pharmaceutica Nv | Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada |
| KR102794804B1 (ko) | 2020-11-30 | 2025-04-10 | 얀센 파마슈티카 엔브이 | 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법 |
| JP7839162B2 (ja) | 2020-11-30 | 2026-04-01 | ヤンセン ファーマシューティカ エヌ．ベー． | パルミチン酸パリペリドン製剤の再懸濁を確実にする方法 |
| MX2024002215A (es) | 2021-08-20 | 2024-05-10 | Janssen Pharmaceutica Nv | Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada. |
| WO2023030870A1 (en) | 2021-08-30 | 2023-03-09 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
-
2021
- 2021-05-07 MX MX2023006370A patent/MX2023006370A/es unknown
- 2021-05-07 FI FIEP21724651.1T patent/FI4025187T3/fi active
- 2021-05-07 KR KR1020237021416A patent/KR20230116837A/ko not_active Ceased
- 2021-05-07 DK DK21724651.1T patent/DK4025187T3/da active
- 2021-05-07 EP EP21724651.1A patent/EP4025187B1/en active Active
- 2021-05-07 AU AU2021387679A patent/AU2021387679B2/en active Active
- 2021-05-07 MA MA71365A patent/MA71365A/fr unknown
- 2021-05-07 TW TW113108928A patent/TWI897289B/zh active
- 2021-05-07 CN CN202180080436.4A patent/CN116507320A/zh active Pending
- 2021-05-07 HR HRP20240086TT patent/HRP20240086T1/hr unknown
- 2021-05-07 PL PL21724651.1T patent/PL4025187T3/pl unknown
- 2021-05-07 PT PT217246511T patent/PT4025187T/pt unknown
- 2021-05-07 SM SM20240075T patent/SMT202400075T1/it unknown
- 2021-05-07 IL IL303251A patent/IL303251A/en unknown
- 2021-05-07 US US17/314,281 patent/US11324751B1/en active Active
- 2021-05-07 LT LTEPPCT/EP2021/062144T patent/LT4025187T/lt unknown
- 2021-05-07 HU HUE21724651A patent/HUE065387T2/hu unknown
- 2021-05-07 CA CA3203448A patent/CA3203448A1/en active Pending
- 2021-05-07 TW TW110116513A patent/TWI838623B/zh active
- 2021-05-07 ES ES21724651T patent/ES2974822T3/es active Active
- 2021-05-07 JP JP2023532443A patent/JP7792409B2/ja active Active
- 2021-05-07 RS RS20240087A patent/RS65133B1/sr unknown
- 2021-05-07 WO PCT/EP2021/062144 patent/WO2022111858A1/en not_active Ceased
- 2021-05-07 SI SI202130112T patent/SI4025187T1/sl unknown
- 2021-05-07 EP EP23219073.6A patent/EP4385564A3/en active Pending
-
2022
- 2022-05-06 US US17/738,422 patent/US12208100B2/en active Active
-
2023
- 2023-05-30 MX MX2024013364A patent/MX2024013364A/es unknown
-
2024
- 2024-01-25 ZA ZA2024/00851A patent/ZA202400851B/en unknown
- 2024-04-10 AU AU2024202306A patent/AU2024202306B2/en active Active
-
2025
- 2025-10-14 JP JP2025172891A patent/JP2026027249A/ja active Pending
-
2026
- 2026-03-12 AU AU2026201895A patent/AU2026201895A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023552149A5 (https=) | ||
| JP2023552329A5 (https=) | ||
| JP3701870B2 (ja) | 末梢血管疾患治療のための９−デオキシ−２’，９−α−メタノ−３−オキサ−４，５，６−トリノール−３，７−（１’，３’−インターフェニ | |
| JP2023551009A5 (https=) | ||
| JP3623962B2 (ja) | ヒドロキソコバラミンの鼻中投与用医薬組成物 | |
| FI4025187T3 (fi) | Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia | |
| JP2012533554A5 (https=) | ||
| JPH05505618A (ja) | 相乗的治療用組成物及び方法 | |
| AU2014235346A1 (en) | Beraprost isomer as agent for the treatment of viral infection | |
| FI4025188T3 (fi) | Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia | |
| JP2014196328A (ja) | ニコチン性アセチルコリンα７受容体アゴニストの組合せ剤 | |
| JP2023535744A5 (https=) | ||
| JPH10158169A (ja) | 塩化トロスピウムを含んだ医薬製剤、その調整方法および使用方法 | |
| MX2009002311A (es) | Composiciones farmaceuticas para tratamiento de infecciones fungales. | |
| US20230181704A1 (en) | Anti-sars-cov-2 virus agent antiprovir | |
| MY195178A (en) | Composition for Treating Joint Disease and Kit Containing Same | |
| US11497747B2 (en) | Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections | |
| Ananth et al. | Benztropine psychosis | |
| WO1996004917A1 (en) | Remedy for myotonic dystrophy | |
| JP3243514B2 (ja) | 療法―抵抗性精神分裂症治療用医薬 | |
| JP2627914B2 (ja) | プロスタグランジン類の選択的作用増強剤 | |
| JPH11503721A (ja) | ベンズアミド誘導体の新規用途 | |
| EP1518554B1 (en) | Pharmaceutical composition for the treatment of hyperhomocysteinemia | |
| US11364218B2 (en) | Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome | |
| JPS6116A (ja) | 有機化合物に関する改良 |